Day One Biopharmaceuticals Posts Narrower $0.20 Loss, 11.4% Q4 Revenue Beat
Day One Biopharmaceuticals reported a Q4 adjusted loss of $0.20/share versus a $0.17/share estimate, narrowing from a $0.69 loss a year ago, while revenue jumped to $53.7 million, surpassing estimates by 11.4% and nearly doubling year-ago sales. Shares have risen 25.5% year-to-date.
1. Q4 Financial Results
Day One Biopharmaceuticals posted an adjusted loss of $0.20 per share for Q4, missing the $0.17 estimate, compared with a loss of $0.69 per share a year earlier. Revenue rose 84% year-over-year to $53.72 million, surpassing projections by 11.4%.
2. Outlook and Analyst Estimates
Consensus for Q1 calls for a loss of $0.15 per share on $47.73 million in revenue, while full-year EPS is forecast at -$0.55 on $228.54 million in sales. Estimate revisions have turned more favorable over the past quarter, indicating potential upside to near-term forecasts.
3. Stock Performance and Drivers
Shares have gained 25.5% year-to-date, outperforming the S&P 500’s 0.1% decline, driven by robust revenue growth and repeated revenue beats. Future stock momentum will hinge on upcoming earnings commentary and sustained estimate revisions.